Pharmacy news, jobs, continuing education, community and more.
LAWRENCEVILLE, N.J. – For teachers exploring new ways to make science and mathematics more interesting – and more relevant – for their students, New Jersey is more than the medicine chest of the world. It is a living laboratory. “RxeSEARCH provides students an opportunity to explore and solve realistic problems in science while also offering [...]
PRINCETON, N.J.-Bristol-Myers Squibb Company (NYSE: BMY) today announced that a clinical trial – known as study 024 – of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Study 024 was designed to assess overall survival in unresectable stage III or stage IV melanoma patients [...]
PRINCETON, N.J.- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeling for REYATAZ® (atazanavir sulfate) to include dose recommendations in HIV-infected pregnant women. In HIV combination therapy, treatment with the recommended adult dose of REYATAZ 300 mg, boosted with 100 mg of [...]
NEW YORK & PRINCETON, N.J. – Bristol-Myers Squibb Company (NYSE:BMY) and Pharmasset (NASDAQ: VRUS) announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb’s NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset’s nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus (HCV). [...]
DEVENS, Mass. – Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has received Leadership in Energy and Environmental Design (LEED®) Silver certification for its biologics manufacturing facility in Devens, Massachusetts. The laboratory and office building at the same facility received LEED Gold certification in December 2009. LEED certification, established by U.S. Green Building Council and [...]
PRINCETON, N.J. & WILMINGTON, Del. – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a [...]
PRINCETON, N.J. & WILMINGTON, Del.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult [...]
Featured Jobs
© Rx Times 2006 - 2012. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.